Peter Wehrwein

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.

Peter Wehrwein, senior editor at Managed Healthcare Executive, spoke with Lisa Griffin, senior vice president of front-end operations at Jefferson Health in Philadelphia, about the pivot to telehealth, "seamless access" and racism.

The risk of long-term use of oral corticosteroids are well known. This research shows that short "bursts" of one to two weeks also carry some risk of adverse events.

Authors of JAMA Oncology opinion piece see priorities set in response to the pandemic as a chance to discourage low-value cancer care.

"I don't know about you, but in March I was scared; now I'm mostly depressed..."

Any rollback needs to be based on evidence, say authors

Company's price is lower than ICER's $50k per-QALY assessment.

Penn's David Fajgenbaum, M.D., MBA, is branching out from Castleman disease to assemble comprehensive registry of drugs to treat COVID-19.

Farzad Mostashari and Ezekiel Emanuel agree: The COVID-19 experience could be what finally weans American healthcare off of its dependence on fee-for-service payment. But they have a slightly different vocabulary and different notions about what might lead to a tipping point.

John D'Amore, president and co-founder for Diameter Health, speaks with Managed Healthcare Executive Senior Editor, Peter Wehrwein, about fast healthcare interoperability resources standards , or FHIR, as they apply to insurers. There are new CMS FHIR regulations for Medicare Advantage and Medicaid managed care plans that go into effect in July 2021. Private insurers are expected to follow suit.

Hospitals have bounced back from April but are still behind from where they were in May 2019.

One way the federal government responded to the COVID-19 pandemic was to temporarily increase the federal Medicaid matching rate by 6.2 percentage points. In exchange, states couldn’t add restrictions to eligibility and had to offer COVID-19 testing and treatment without cost sharing.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

Members of a federal commission charged with studying COVID-19 in nursing homes have been named.

The "conservative estimate" assumes that disruption of services ends in six months.

Utilization and revenue were half of March and April 2019 levels for oral surgery, cardiology, dermatology, gastroenterology, and orthopedics.

Website, media campaign designed to encourage Philadelphians who need help to seek it.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials.

Survey of over 1,000 people shows that use of telehealth has tripled.

Kathi Mooney, Ph.D., RN, FAAN, interim senior director of population sciences at the Huntsman Cancer Institute in Salt Lake City, discusses hospital-at-home programs and how they are common in countries with single-payer systems and include patients with conditions ranging from cellulitis to heart failure. The benefits include the familiarity of home surroundings, avoidance of hospital-acquired infection, and less de-conditioning from being in a hospital bed.

Conversations with commercial payers about reimbursement mechanisms is a next step, says researcher Kathi Mooney.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.